Last week, the Food and Drug Administration (FDA) heard the heart-wrenching personal stories of individuals whose lives have been devastated by Alzheimer’s disease.

The Alzheimer’s Association worked directly with the FDA to arrange this session as part of our advocacy for new treatments. We were deeply concerned that the voices of those diagnosed with Alzheimer’s and their caregivers had not truly been heard during a recent advisory committee meeting on aducanumab, an Alzheimer’s treatment developed by Biogen, now under review by the FDA.

On behalf of the millions of Americans facing Alzheimer’s every day, the speakers candidly and powerfully used their voices to communicate the immediate need for treatment to FDA leaders. We are deeply grateful to each of the speakers, who so openly, and often emotionally, talked about the crushing impact of Alzheimer’s on their own lives and the lives of their loved ones.

Hearing the staggering realities of living with Alzheimer’s, with no treatment available for its underlying cause, the FDA participants were certainly engaged and expressed their appreciation for the speakers’ openness and honesty.

I told the FDA leaders that the Alzheimer’s Association, as a science-driven organization, continues to believe what we have told them previously, that aducanamab should be approved.

If approved, it would be the first treatment to potentially change the progression of Alzheimer’s, not just the symptoms. We believe the accumulated science, the publicly released data on aducanumab and the absence of any other treatment addressing the cause of the disease justifies FDA approval, accompanied by a Phase 4 post marketing surveillance study.

Be assured, we will keep working on this on behalf of the millions affected by Alzheimer’s until a decision is made. And then, whatever the decision, we’ll continue to work relentlessly until we realize our vision of a world without Alzheimer’s.

I will share more news with you when the FDA makes its final decision. As always, thank you for everything you do to advance our mission to make a difference for others — today and tomorrow.

Harry Johns

Chief Executive Officer

This discussion has been closed for comment. Start a New Discussion.
Is this discussion on youtube?

Thanks for sharing, joel.

This letter is taken from the Alzheimer's Impact Movement update. AIM is the policy arm of the Alz Assn. Aducanumab is an anti body that targets amyloid-beta which is a prime suspect in AD formation. Because amyloid beta has been the focus of most AD research, and until now all trials have failed, many scientist believe that more effort should be placed on the tau protein or even another protein not yet researched. Additionally, many cases of AD show no signs of either A/B or tau protein. Finding a treatment has been very evasive. If FDA approved, this drug could be a small step towards AD treatment but certainly not a panacea. However, any small step is a good step.

I myself am grieving over the loss my wife of 54 years due to Alzheimer's her life was terminated when she was infected with the virus in a nursing home in April of 2020 by covid 19 complication Thank g-d they finally are able to treat this terrible disease. Thanks to peter King and other NYS legislator that help to get funds to be able to treat this devastating disease.

This discussion has been closed for comment. Start a New Discussion.
Start a Discussion
Subscribe to
Our Newsletter